Healios is engaged in the development of cellular and tissue-based products, which are expected to be novel therapies for various diseases.
Below are the product pipelines we are currently working on.
Please refer to the page Development of Treatments for Age-Related Macular Degeneration (AMD) involving transplantation of iPS cell-derived retinal pigment epithelial (RPE) cells as an iPSC regenerative medicine.
Please refer to the page Development of Organ Anlage Transplantation Therapy involving a technology to create functional human organs using pluripotent stem cells (such as iPS cells).
Development of regenerative medicine using MultiStem for ischemic stroke.